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Abstract
Background: Cancer related thrombosis not only increases morbidity and mortality but also poses a significant
financial burden on health care system. Risk of venous thromboembolism (VTE) in these patients substantially
increases with the addition of chemotherapy. Lately, cisplatin has been implicated as an independent factor. There
is little data estimating the risk of venous thromboembolism in patients receiving cisplatin based chemotherapy
when compared to other chemotherapeutic agents.
Methods: Patients who had received chemotherapy between November 2010 and October 2012 were
retrospectively identified from a single institute cancer registry. 200 patients who had received cisplatin based
chemotherapy were identified as the exposed group while 200 patients who had received non-Cisplatin based
regimens were identified as the non-exposed group. Patients were followed for development of VTE throughout
the entire duration of therapy and one month thereafter. Cox proportional hazard model was used to compute
relative risks with 95% confidence intervals.
Results: The baseline characteristics were similar in the two groups. Mean age for the entire cohort was 55.4 ± 10.
7 years and male to female ratio was almost 1:1. On univariate analysis, cisplatin based chemotherapy, presence of
central venous catheter, female gender, poor performance status, high risk stratification according to the Khorana
model and use of granulocyte colony stimulating factor were all significantly associated with the development of
VTE. The crude relative risk for the incidence of VTE in cisplatin group was 2.8 (95% CI, 1.4 – 4.2) times compared to
the non-Cisplatin group. When the relative risk was adjusted for the above variables in multivariable analysis, it
increased to 3.3 (95% CI, 1.6 – 6.8) compared to the control group.
Conclusion: A high incidence of VTE in patients receiving cisplatin based chemotherapy was demonstrated in this
study. Prospective studies are warranted to establish this observation with certainty and to explore the possible use
of thromboprophylaxis in patients receiving cisplatin based chemotherapeutic regimens.
Keywords: Cisplatin, Chemotherapy, Venous thromboembolism

Background
There is a substantial risk of venous thromboembolic
events (VTE) in patients with cancer. The incidence
of VTE in the general population is approximately
117 per 100,000, whereas the incidence in patients
with cancer is approximately one in 200 [1, 2]. A
large cohort study showed that the baseline risk of
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thrombosis in cancer is approximately 4.1 folds compared to the healthy population while it increases to
6.5 fold after the addition of chemotherapy [3]. This
leads to reduction in survival of patients with malignancy and increased expense of treatment and care
[4–6]. Although individual factors including the
tumor type, stage, recency of cancer diagnosis, presence and number of co-morbidities define risk of
VTE in cancer, active therapy with certain chemotherapeutic agents has been contemplated as an additional
risk factor [7]. There is anecdotal evidence of
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increased incidence of VTE in patients receiving
Cisplatin based regimes [8, 9]. Studies in urothelial,
germ cell and non-small cell lung cancer (NSCLC)
patients have established a link between Cisplatin and
increased incidence of VTE [10–12]. Another recent
large retrospective study showed the prevalence of
VTE to be 16.6% in all patients treated with Cisplatin
[13] which is significantly higher than 7.3% for VTE
in patients treated with any chemotherapy [14]. Prospective randomized controlled trials in patients with
advanced esophagogastric junction (EGJ) or gastric
adenocarcinoma showed that this thrombogenic effect
is not class specific for all the platinum containing
chemotherapeutic agents, but only Cisplatin based
chemotherapy is associated with a statistically significant greater number of VTE events than Oxaliplatin
[15, 16]. Recently, a meta-analysis from case series
and some pre-clinical trials provided evidence of high
risk of VTE in patients receiving Cisplatin based regimens [17].
Various hypotheses exist pertaining to the mechanisms
associated with Cisplatin associated thrombosis including direct damage to the vascular endothelium, increased procoagulant activity, reduced anticoagulation
synthesis, platelet activation and aggregation and vascular inflammation [18–24].
Despite increasing evidence pertaining to the
thrombogenic potential of Cisplatin, no original analytical study has thus far investigated the magnitude of increased risk of VTE imparted by Cisplatin based
chemotherapies when compared to other chemotherapies. Hence, it is extremely important to quantify this
risk in order to advocate prophylaxis with antiplatelets
or anticoagulants and hence reduce the economic and
health care associated burden of VTE caused by
Cisplatin based chemotherapy. Therefore we aimed to
quantify the risk and identify high risk groups so that
treatment is targeted and benefits maximized. Prophylactic anticoagulation for all cancer patients is expensive
and has a narrow therapeutic index and hence not practical. We hypothesized that there is an increased risk of
VTE in cancer patients receiving Cisplatin based chemotherapy regimens compared to other chemotherapies.

Methods
This is a retrospective cohort study including all adult
cancer patients presenting to the oncology ward or
day care centre of the Aga Khan University Hospital
for chemotherapy. Cancer patients receiving Cisplatin
based chemotherapy regimens were considered exposed while those cancer patients receiving chemotherapy regimens which do not contain Cisplatin
comprised the unexposed group. Adult (>16 years)
participants were considered eligible if they received
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treatment between November 1, 2010 and October
31, 2012. They should have initiated and completed
all treatment at Aga Khan University Hospital while
maintaining a followup of atleast 1 month post completion of treatment or until death, whichever came
first. Excluded were those on antiplatelets agents or
anticoagulants, with a previous history of DVT or PE
(self-reported), known pro-thrombotic disorders or
hyper-coagulable states, patients who were on
erythropoiesis-stimulating agent (ESA) during chemotherapy or up to 6 weeks prior to the first cycle of
chemotherapy and those female patients who were on
oral contraceptive pills.
All cancer patients treated in the day care centre or
the inpatient oncology wards of Aga Khan University
Hospital between November 1, 2010 and October 31,
2012 were identified through the discharge coding
system. 100 consecutive eligible patients were included in each group starting from November 1, 2010
(Fig. 1). Medical record files were reviewed for demographic and clinical data which was recorded on a
pre-designed questionnaire. Confounding factors such
as the presence of indwelling central line, obesity and
family history of DVT were recorded if present. All
identified patients were followed up during the course
of chemotherapy and at least 4 weeks post chemotherapy. Radiological investigations for the study
population were also reviewed to make sure that no
cases of VTE are missed. In case of discrepancy between the chart data and radiological investigations,
the patient was telephonically evaluated for the history of VTE event or the use of anticoagulant agents
during the specified time period. Outcome was any
VTE event during chemotherapy or within 4 weeks
after the completion of chemotherapy. ECOG classification was modified for analysis as class 0, 1 and 2
were combined as “good”, while class 3 and 4 was
“poor”. Class 5 was excluded. Khorana score was categorized as low risk (0 points), intermediate risk (1–2
points) and high risk (3 or more points).

Outcome
Venous thromboembolism

Venous Thromboembolism was defined as the occurrence of a thromboembolic event after atleast 3 days of
initiation of chemotherapy up to 4 weeks of the completion of chemotherapy cycle. This included any deep venous thrombosis and/or pulmonary embolism as under:
1. Evidence of venous thromboembolism on Computed
Tomography Chest.
2. Evidence of DVT anywhere in the body on
radiological evaluation including ultrasound, CT
scan or MRI within the period defined above
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Fig. 1 Flow chart of participants in the study. *Aga Khan University Hospital, Karachi, Pakistan

3. Cause of death/morbidity defined as Pulmonary
Embolism by primary physician.
4. For patients who develop signs and symptoms of
VTE but died before diagnostic criteria could be
met, sudden, otherwise unexplained death was taken
as a VTE event in the presence of severe hypoxia on
ABGs and no acute change in chest
X-ray.
With a confidence level of 95%, power of 80% and
considering the prevalence of venous thromboembolism in cancer patients receiving chemotherapy to be
around 7.3% while the anticipated prevalence after receiving Cisplatin chemotherapy to be 16.6% the minimum sample size in each group to refute the
hypothesis of equality of proportions was 200 [14].
Patients were enrolled after informed consent. Ethical
approval was taken from the Institutions’ Ethics
Committee under approval number 2703-Med-ERC2013. Complete confidentiality of all patient information and personal data was ensured.
Statistical analysis

Mean ± SD was reported for continuous variables and
percentages and proportions for categorical variables. Cox
proportional hazard model was used to calculate crude
and adjusted Relative risks and 95% confidence interval

for incidence of VTE. p value < 0.05 was considered
significant. Data was analysed using Stata version 12.

Results
The mean age of Cisplatin group was 56(11.9) years while
in the non-Cisplatin groups it was 55(9) years. There was
a slight preponderance of males in both groups (Table 1).
Most of the cancers were metastatic in both groups and
very few were early stage malignancies (Tables 2 and 3).
Less than 10% of the whole cohort had ECOG poor status.
129(64.5%) participants in Cisplatin group had intermediate Khorana risk score as compared to 125(62.5%) in the
Non-Cisplatin group. 29% of the patients had an indwelling central venous catheter (CVC) at some point during
the study in the Cisplatin group vs. 27% in the non-Cisplatin group. Details of the chemotherapy regimens used in
both groups have been highlighted in Tables 4 and 5
whereas important co-morbids in the two cohorts have
been summarized in Table 6.
When the dose of Cisplatin was considered, we found
that 31 VTE events occurred when the mean (SD) cumulative dose of Cisplatin was 471(133) mg/m2 while in
the group without events the mean cumulative dose was
322(124) mg/m2 (Table 7).
Among the VTE events most were DVTs i.e.18 in
Cisplatin group while 7 in non-Cisplatin group
(Appendix 1). Among those who suffered a VTE event, 4
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Table 1 Baseline Characteristics of the participants
Variables

Cisplatin Group
n = 200 n (%)

Non-Cisplatin Group
n = 200 n (%)

1 Age (yrs)a

56 (11.9)

55 (9)

2 Males

108 (54%)

104 (52%)

3 Time to VTE (days)a

58 (17)

56 (13)

4 Stage

Table 2 Cancer type and stage of patients receiving cisplatin
based chemotherapy
Site of cancer

Stage of tumor (N = 200)
Early
(%)

Total (%)

Locally
Metastatic
advanced (%) (%)

Lung

1 (0.5) 16 (8)

21 (10.5)

38 (19)

Gastric/GEJ

2 (1)

10 (5)

20 (10)

1 (0.5) 14 (7)

19 (9.5)

34 (17)

9 (4.5)

13 (6.5)

0

6 (3)

8 (4)

Early

10 (5%)

12 (6%)

Head and Neck

Locally advanced

86 (43%)

92 (46%)

Pancreatic

0

104 (52%)

96 (48%)

Ovarian

1 (0.5) 5 (2.5)

58 (29%)

55 (27%)

Esophageal

1 (0.5) 6 (3)

9 (4.5)

16 (8)

3 (1.5) 1 (0.5)

9 (4.5)

13 (6.5)

Metastatic
5 Presence of CVC

4 (2)

6 Surgery in 2 months

44 (22%)

56 (28%)

Germ Cell

7 ECOG poor

16 (8%)

12 (6%)

Cervical/Vulvar

0

3 (1.5)

7 (3.5)

10 (5)

Bladder

0

5 (2.5)

7 (3.5)

12 (6)

8 Khorana Risk
low

39(19.5%)

55 (27.5%)

Endometrial

1 (0.5) 3 (1.5)

0

4 (2)

0

2 (1)

4 (2)

intermediate

129 (64.5%)

125 (62.5%)

Chloangiocarcinoma

high

32 (16%)

20 (10%)

Breast

0

3 (1.5)

3 (1.5)

6 (3)

Carcinoma of unknown
primary (CUP)

0

6 (3)

2 (1)

8 (4)

Gall bladder/
peri-ampullary

0

4 (2)

3 (1.5)

7 (3.5)

0

9 (4.5)

9 Use of GCSF
never

88 (44%)

86 (43%)

<50% of cycles

71 (35.5%)

81 (40.5%)

>50% of cycles

6 (3%)

24 (12%)

Lymphomaa

(9 9.5%)

a

All cycles

35 (17.5%)

2 (1)

9 (4.5)

Lymphoma can only be classified into early or advanced stage

a

Mean(SD)

died in Cisplatin group while 1 in non-Cisplatin group
(Appendix 2). On univariate analysis other than
Cisplatin based chemotherapy, poor ECOG status,
presence of CVC and Khorana risk score were
statistically significant (Appendix 3). These were used
for final model building.
The crude relative risk of VTE in the Cisplatin
group was 2.8 (95% CI: 1.4–4.22) times higher than
in the Non-Cisplatin group (Table 8). When adjusted
by gender, ECOG status, GCSF, presence of CVC and
Khorana risk score the adjusted relative risk was
3.32(95% CI:1.6–6.8) (Table 9).

Discussion
This study reports a high risk (RR: 3.3, 95% CI: 1.6–
6.8) of VTE in cancer patients receiving Cisplatin
based chemotherapy. Cisplatin is a platinum based
drug which is used for the treatment of cancer. The
mechanism of causing VTE is not clear but endothelial injury, hypomagnesemia and increased levels of
Von Willebrand’s factor are involved [8, 19–21, 23].
Patient factors including female sex, age, type of
cancer, Khorana risk and indwelling CVC further
elevate the risk of VTE [13]. In our study Khorana
risk and presence of CVC were found to be

significantly associated with this risk. Another interesting
finding, which has not been explored previously, is the risk
of VTE with higher cumulative doses of Cisplatin (Table 3).
In our study, cumulative Cisplatin dose of more than
450 mg was associated with VTE events.

Table 3 Cancer type and stage of patients receiving non-cisplatin
based chemotherapy
Site of cancer

Stage of tumor (N = 200)
Early
(%)

Total (%)

Locally
Metastatic
advanced (%) (%)

Lung

1 (0.5) 6 (3)

7 (3.5)

14 (7)

Gastric/GEJ

0

8 (4)

8 (4)

16 (8)

Pancreatic

0

8 (4)

6 (3)

14 (7)

Ovarian

0

7 (3.5)

9 (4.5)

16 (8)

Endometrial

0

3 (1.5)

3 (1.5)

6 (3)

Breast

4 (2)

28 (14)

28 (14)

60 (30)

Colorectal/Anal/Small
bowel

5 (2.5) 17 (8.5)

22 (11)

44 (22)

Lymphomaa

1 (0.5) 11 (5.5)

Sarcoma

1 (0.5) 7 (3.5)

4 (2)

12 (6)

Others

0

5 (2.5)

6 (3)

a

1 (0.5)

12 (6)

Lymphoma can only be classified into early or advanced stage
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Table 4 Chemotherapy regimens received by patients in the
cisplatin group

Table 6 Comparison of the co-morbidities present in the two
groups

Type of chemotherapy

Number of patients
(%) N = 200

Co-morbid

Cisplatin + Gemcitabine

58 (29)

N = 200

N = 200

Cisplatin + Concurrent chemoradiation

28 (14)

Diabetes Mellitus

30 (15)

24 (12)

Cisplatin + 5-FU/Cisplatin + Capecitabine

8 (4)

Hypertension

46 (23)

52 (26)

Cisplatin + 5-FU + Radiation/Cisplatin +
Capecitabine + Radiation

7 (3.5)

Coronary artery disease

10 (5)

08 (4)

Prior Atrial fibrillation

04 (2)

04 (2)

Docetaxel + Cispaltin + 5-FU

30 (15)

Epirubicin + Cisplatin + 5-FU/Epirubicin + Cisplatin

10 (5)

Docetaxel + Cispaltin + 5-FU + Cetuximab

4 (2)

DHAP (Dexamethasone + High dose ARA-C +
Cisplatin)

8 (4)

Cisplatin + Etoposide/Cisplatin + Etoposide +
Bleomycin

12 (6)

Cisplatin + Pemetrexed

16 (8)

Cisplatin + Navelbine

15 (7.5)

Cispaltin + Gemcitabine + Radiation

4 (2)

Our risk estimates are higher than a previously
reported meta-analysis where the risk was 1.67 (95%
CI: 1.25–2.23). The reason for this may be Seng et al,
in their meta-analysis pooled results from phase II to
III clinical trials. It is possible that patients in their
study were a highly selective group. Another
Table 5 Chemotherapy regimens received by patients in the
non-cisplatin group
Type of chemotherapy

Number of patients
(%) N = 200

Capecitabine + Oxaliplatin/5-FU + Leucovorin +
Oxaliplatin/Epirubicin + Oxaliplatin + Capecitabine

34 (17)

5-FU + Irinotecan + Leucovorin/5-FU + Irinotecan +
Leucovorin + Cetuximab/Irinotecan + Cetuximab

18 (9)

Doxorubicin + Cyclophophamide/5-FU + Epirubicin 24 (12)
+ Cyclophophamide/Epirubicin + Cyclophophamide
Paclitaxel/Paclitaxel + Herceptin

22 (11)

Docetaxel/Docetaxel + Herceptin

26 (13)

Adrimacycin + Ifosfamide

8 (4)

Carboplatin + Paclitaxel

34 (17)

CHOP/ABVD (Cyclophosphamide + Adriamycin +
Vincristine + Prednisone)/(Adriamycin + Bleomycin
+ Vinblastine + Dacarbazine)

12 (6)

VAC alternating with IE (Vincristine + Adriamycin +
Cyclophosphamide alternating with Ifosfamide
+ Etoposide)

4 (2)

5-FU + Oxaliplatin + Irinotecan + Leucovorin

8 (4)

Gemcitabine

6 (3)

Carboplatin + Gemcitabine
Others

Number in cisplatin Number in noncisplatin
group (%)
group (%)

Prior history of TIA/Stroke 02 (1)

00

Renal Failure

00

00

Heart Failure

00

00

explanation could that we had highly specialised
investigations available and the chances of diagnosing
a VTE are higher in the present era than between
1990 and 2010 which is the study time for Seng et
al’s study [17].
The reason for choosing one month follow-up was
twofold. One, previous literature [13] had also taken
one month follow-up for development of DVT in
patients receiving Cisplatin based chemotherapy. This
study reported that 88% of patients developed TEE
within 100 days of initiation of treatment with
Cisplatin based regimens. Hence a period of 30 days
post completion of chemotherapy seems a reasonable
follow-up period for capturing most, if not all, events
occurring as a result of the drug intervention.
Secondly, we believe it is safe to assume that since
re-dosing of Cisplatin as a chemotherapeutic agent is
required within 3–4 weeks of the last dose; most
therapeutic as well as adverse effects of the drug are
neutralised within one month of last dosing. Moreover, if a VTE occurs one month after completion of
chemotherapy, it becomes further complex to attribute it solely to chemotherapy effects as underlying
disease and other risk factors (e.g. CVC, immobility
etc.) are likely to play a much more important role.
Our major strength is being the first original research reporting relative risk of VTE in Cisplatin
based regimens compared to non-Cisplatin. Aga Khan
University hospital is one of the two large centres for
the treatment of cancer in Pakistan. Hence, we were

Table 7 Effect of Cisplatin dose on incidence of VTE
VTE status

Cumulative dose of Cisplatin
(mg/m2) Mean (SD)

2 (1)

VTE occurred n = 31

471 (133.4)

2 (1)

VTE did not occur n = 169

322 (124)

Zahir et al. BMC Cancer (2017) 17:57
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Table 8 Crude Relative Risk of Venous Thromboembolism in
Cisplatin based regimens
Incidence proportion

Relative Risk (95% CI)

Cisplatin group

31/200

2.81* (1.4–4.2)

Non-Cisplatin group

11/200

*p < 0.05

able to obtain a reasonable sample with reliable data
on patients from the time of starting Cisplatin therapy up till one month post chemotherapy. We were
able to maintain close follow up with all our patients
without attrition. There was no missing information
because we had access to medical records and
patients were coming for clinical follow ups regularly.
We chose a retrospective study design for feasibility
of sample size achievement and save resources.
The data was collected retrospectively but since all
the parameters were measured and documented in
hospital notes we assume there is minimal bias due
to recall. Although we may have missed some important confounders, one advantage of using hospital data
in this study was that the medical details were very
accurate and radiological investigations were easy to
follow hence minimizing misclassification of exposure
and outcome.
Site of cancer could be an important confounder
hence it was incorporated as one of the predictors of
Khorana score and it is reflected within the scoring.
Accordingly, we have adjusted our final model for
Khorana score to eliminate any confounding effect that
may have arisen due to the site of disease.
Polychemotherapy may potentially attribute higher
rates of VTE than single agent chemotherapy but this
fact is unlikely to affect our results as almost all
patients in both the groups received combination
chemotherapy (Tables 4 and 5). Patients who received
other platinum based therapies
(Carboplatin,
Oxaliplatin), were included in the non-Cisplatin group
further highlighting the possibility that the increased
thrombogenic effect may be inherent to Cisplatin
alone rather than to the entire group of platinum
drugs.

This however, is also a potential bias and limitation
of our study as a difference in VTE incidence
between the different platinum drugs was not explored further. Our study had not been designed to
evaluate for any differences in VTE incidence between
the platinum compounds but further dissection and
analysis could indeed prove very interesting and is an
area which needs to be explored in future studies.
Another potential limitation of our study is the
absence of a universal screening test for assessment
of VTE status prior to initiation of chemotherapy in
patients. Although this would have been the ideal
method to ensure absence of VTE (target end-point)
in newly recruited patients, the retrospective nature
of our study meant that we had no control over investigations performed both prior to and during the
course of the study.
In the light of these finding we think there is an urgent need to prospectively estimate the risk of VTE
in patients receiving Cisplatin based regimens. It is
immensely important to discover the pathophysiology
and identify genetic and molecular mechanisms of occurrence of VTE in these patients. Till then we
strongly recommend prophylaxis against VTE in high
risk groups to avoid serious morbidity or mortality.
We emphasize that it is extremely important to
develop potent and effective chemotherapeutic agents
with fewer side effects.

Conclusion
In our experience this is one of the first reports of
risk estimates of VTE with Cisplatin based
chemotherapeutic regimens. Focus should be laid on
discovery of newer and safer chemotherapeutic agents.
Till then, prophylaxis against VTE for patients
receiving Cisplatin based chemotherapy is highly
recommended. It is important to identify high risk
groups vulnerable to this side effect.
Appendix 1

Table 10 Venous thromboembolic Events in Cisplatin based
and Non-Cisplatin based Chemotherapeutic regimes
Venous Thromboembolic
Events

Table 9 Adjusted Relative Risk of VTE due to Cisplatin based
Chemotherapy

Cisplatin based chemotherapy

Cisplatin
group

Non-Cisplatin
group

n = 200

n = 200

DVT alone

18

7

β
coefficient

SE
(β)

Relative
Risk

95% CI
for RR

PE alone

7

2

DVT + PE

5

2

1.2

0.37

3.32

1.6–6.8

Sudden death (defined as VTE)

1

0

Total

31

11

adjusted for ECOG, Khorana risk score, GCSF, presence of CVC and gender-log
likelihood =471.38

p value

0.02
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Appendix 2

and during manuscript preparation. All authors read and approved the final
manuscript.

Table 11 Patient outcomes after Venous Thromboembolic
Events
Patient status
after VTE

Cisplatin group
N = 31

Non-Cisplatin group
N = 11

Dead

4

1

Alive

27

10

Competing interests
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Consent for publication
Not applicable.

Appendix 3

Ethics approval and consent to participate
The study received exemption from ethical approval by the Institutional
Review Board (IRB) of the Aga Khan University Hospital, Karachi, Pakistan
(Committee Reference Number: 2703-Med-ERC-13).

Table 12 Risk factors for venous thromboembolism in cancer
patients

Author details
1
Department of Oncology, Aga Khan University Hospital, Stadium Road, PO
BOX: 3500, Karachi 74800, Pakistan. 2Department of Medicine, Aga Khan
University Hospital, Stadium Road, PO BOX: 3500, Karachi 74800, Pakistan.

Variable

β coefficient

SE

P value

1 Cisplatin based chemotherapy

1.034

0.35

0.003

2 Age (years)

0.01

0.015

0.42

3 ECOG poor

0.79

0.44

0.07

4 Female

0.41

0.31

0.19

5 GCSF never

0

< 50% of the cycles

0.13

0.37

> 50% of the cycles

0.87

0.45

all

0.15

0.51

6 Stage early

0.17

0

locally advanced

−0.42

0.63

metastatic

−0.17

0.61

7 CVC present

0.74

0.31

8 Khorana Risk low

0

0.67
0.01
0.07

intermediate

−0.91

0.46

high

−0.85

0.37
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